A single-use platform for intensified viral vector purification
Sponsored by: Sartorius Stedim Biotech
- Viral Vector Purification
Date: 3 December
Time: 3PM London/10AM New York
Accelerate viral vector vaccines development and increase productivity
Viral vector-based vaccines are a promising field in vaccinology and are taking more importance in the overall vaccine pipeline. They elicit a strong immune response in patients, avoid the use of highly pathogenic viruses – such as Ebola – and most important are “platform-able”. It allows firms to reduce the time and cost of bringing their vaccines to the clinic thus shortening the time to market. However, viruses are complex entities to produce and purify. The downstream process should be able to remove process and product related contaminants while maintaining the infectious titer, which is a challenge. Nevertheless, innovations in the field of bioprocessing, analytics and data management are driving an increase of overall productivity, getting a better understanding of the process and adapting the platform efficiently to the different indications.
This presentation will describe how the first high throughput ambr® multi parallel testing tool applied to downstream and Design of Experiment software can simplify and accelerate viral vector purification process development. A case study on an Adenovirus at a 20L scale will show how membrane chromatography and large-cut off cross-flow cassettes can further simplify and intensify the purification process of common viral vectors used for vaccines.
The author will finally show how the implementation of fully contained single use technologies like single-use centrifugation, new generation analyzers like the Virus Counter® and SIMCA®-on line multivariate monitoring tools can increase process flexibility and safety, provide predictive process control and lead to robust and cost effective instead downstream manufacturing processes.
Please register to reserve your spot for this exciting webinar and we look forward to welcoming you to our presentation.
Marketing manager – New Generation Vaccines
Amélie Boulais is Marketing Manager – new generation vaccines – at Sartorius Stedim Biotech. She is analyzing the trends of the vaccine industry in order to define best-in-class solutions with the required associated Process Development support and related services for vaccine applications. She started her collaboration with Sartorius in 2008 and held various positions, supporting and advising actors of the bio-industry in their development from Upstream to final filling operations, with a focus on downstream processing and virus clearance. Amélie is graduated from the ENSTBB (the Biotechnology Engineering institute of Bordeaux, France) and holds a Biotechnology Engineer degree.
Key Learning Objectives
- Understand solutions to intensify viral vector purification
- Discover tools to speed-up process development
- Configure single-use process scale equipment for viral vectors purification
- Learn how data analytics can be used for predictive control
- Process Development Scientists
- Process Development Managers
- Process Engineers
- Engineering Directors